XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW013K6
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW013K6 is a billable ICD-10-PCS procedure code for Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. The Alphabetic Index lists this code under Leronlimab Monoclonal Antibody. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Potential COVID-19 therapies.

Code Identity

ICD-10-PCS Code
XW013K6
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
Short Description
Introduce Leronlimab in Subcu, Perc, New Tech 6
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/TechnologyKLeronlimab Monoclonal Antibody
7Qualifier6New Technology Group 6

In the ICD-10-PCS Alphabetic Index

The FY 2027 ICD-10-PCS Alphabetic Index refers to XW013K6 as Leronlimab Monoclonal Antibody. These index entries lead to this code:

Leronlimab Monoclonal Antibody
Direct entry for this code
New Technology, Leronlimab Monoclonal Antibody
Direct entry for this code
Iloprost
Leads to this code's table
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table
CD24Fc Immunomodulator
Leads to this code's table

To code leronlimab monoclonal antibody, open the FY 2027 ICD-10-PCS Alphabetic Index at Leronlimab Monoclonal Antibody. The entry lists XW013K6 directly as a complete, billable code.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM019
Potential COVID-19 therapies
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • XW013F5 — Introduce New Tech Therap in Subcu, Perc, New Tech 5

Similar Procedure Codes

Questions About XW013K6

Is XW013K6 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 on inpatient claims from October 1, 2026 through September 30, 2027.

What is the ICD-10-PCS code for leronlimab Monoclonal Antibody?

The ICD-10-PCS Alphabetic Index lists Leronlimab Monoclonal Antibody under code XW013K6, Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6, billable on inpatient claims in fiscal year 2027.

What do the characters in XW013K6 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character K is the Device/Substance/Technology (Leronlimab Monoclonal Antibody); the 7th character 6 is the Qualifier (New Technology Group 6).